Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
NCCN Hematologic Cancers Highlights
NCCN Unveils New Clinical Guidelines for Myelofibrosis
By
Nick Bryant
NCCN Hematologic Cancers Highlights
November 2016, Vol 7, No 10
New York, NY—Myeloproliferative neoplasms (MPNs) include myelofibrosis, polycythemia vera, and essential thrombocytopenia, and affect an estimated 295,00 individuals in the United States. MPNs represent a diverse array of diseases. This has led to the generation of various treatment guidelines that are often contradictory and difficult to interpret. However, the National Comprehensive Cancer Network (NCCN) is developing a unified field theory on the diagnosis and treatment of MPNs.
Read Article
Shifting Treatment Paradigms for Multiple Myeloma
By
Nick Bryant
NCCN Hematologic Cancers Highlights
November 2016, Vol 7, No 10
New York, NY—How to integrate the many new drugs recently approved for multiple myeloma into clinical practice was a topic addressed by Carol Ann Huff, MD, Director of the Myeloma Program at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, at the 2016 National Comprehensive Cancer Network (NCCN) Congress on Hematologic Malignancies.
Read Article
Rethinking Radiotherapy for Early-Stage Hodgkin Lymphoma
By
Nick Bryant
NCCN Hematologic Cancers Highlights
November 2016, Vol 7, No 10
New York, NY—In a presentation at the 2016 National Comprehensive Cancer Network (NCCN) Congress on Hematologic Malignancies, Ranjana H. Advani, MD, Saul Rosenberg Professor of Lymphoma, Stanford University Medical Center, CA, and Vice Chair of the NCCN’s non-Hodgkin and Hodgkin lymphoma guidelines panel questioned the necessity of using radiotherapy in patients with stage I or stage II Hodgkin lymphoma.
Read Article
Are We Making Progress in Acute Myeloid Leukemia?
By
Nick Bryant
Leukemia
,
NCCN Hematologic Cancers Highlights
November 2016, Vol 7, No 10
New York, NY—Acute myeloid leukemia (AML) was a hot topic at the 2016 National Comprehensive Cancer Network (NCCN) Congress on Hematologic Malignancies. Jessica K. Altman, MD, Associate Professor of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, assured attendees that time was not standing still for patients with AML.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma